Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: What factors most influence enrollment?

Journal of Palliative Medicine

Volumn 16, Issue 3, 2013, Pages 256-262

  Jimenez, Rachel ^a   Zhang, Baohui ^b   Joffe, Steven ^b   Nilsson, Matthew ^b   Rivera, Lorna ^c   Mutchler, Jan ^c   Lathan, Christopher ^b   Paulk, M Elizabeth ^d   Prigerson, Holly G ^b,e  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CAUCASIAN; CLINICAL TRIAL (TOPIC); DEATH; DRUG SCREENING; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HEALTH INSURANCE; HUMAN; INTERVIEW; LIFE EXPECTANCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINORITY GROUP; NATIONAL HEALTH ORGANIZATION; PATIENT CARE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PERFORMANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RACE; RACE DIFFERENCE; SOCIOECONOMICS; TERMINAL CARE; TERMINALLY ILL PATIENT; TREATMENT PLANNING;

CLINICAL TRIALS AS TOPIC; ETHNIC GROUPS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PARTICIPATION; PATIENT PREFERENCE; PHYSICIAN-PATIENT RELATIONS; PROSPECTIVE STUDIES; TERMINALLY ILL;

EID: 84874485707     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2012.0413     Document Type: Article

References (20)

1. National Institutes of Health: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. http://grants.nih. gov/grants/funding/ women-min/guidelines-update.htm (Last accessed October 1, 2011).
2. Murthy VH, Krumholz HM, Gross CP: Participation in cancer clinical trials. JAMA 2004;291:2720-2726.
3. Ford JG, Howerton MW, Lai GY, et al.: Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review. Cancer 2007;112:228-242.
4. Tejeda HA, Green SB, Trimble EL, et al.: Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996; 88:812-816.
5. Bhargava A, Du XL: Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph nodepositive, operable breast cancer. Cancer 2009;115(13):2999-3008.
6. Schwartz K, Powell IJ, Underwood W III, George J, Yee C, Banerjee M: Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology. 2009;74:1296-302.
7. Greiner KA, Perera S, Ahluwalia JS: Hospice usage by minorities in the last year of life: Results from the National Mortality Followback Survey. J Am Geriatr Soc 2003; 51:970-978.
8. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949, pp. 199-205.
9. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
10. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
11. Cohen SR, Mount BM, Strobel MG, et al.: The McGill Quality of Life Questionnaire: Ameasure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med 1995;9:207-219.
12. Mack JW, Block SD, Nilsson M, Wright A, Trice E, Friedlander R, Paulk E, Prigerson HG: Measuring therapeutic alliance between oncologists and patients with advanced cancer: The Human Connection Scale. Cancer 2009;115: 3302-3311.
13. Baggstrom MG, Wagar SN, Sezhiyan AK, et al.: Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. Thorac Oncol 2011;6:98-102.
14. Klamerus JF, Bruinooge SS, Ye X, et al.: The impact of insurance on access to cancer clinical trials at a comprehensive cancer center. Clin Cancer Res 2010;15:16:5997-6003.
15. Lara PN, Higdon R, Lim N, et al: prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 200119:1728-1733.
16. Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, et al.: Are racial and ethnic minorities less willing to participate in health research? PLoS Med 2006;3:e19.
17. Wright AA, Mack JW, Kritek PA, et al.: Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer 2010;116:4656-4663.
18. Loggers ET, Maciejewski PK, Paulk E, et al.: Racial differences in predictors of intensive end-of-life care in patients with advanced cancer. J Clin Oncol 2009;27:5559-5564.
19. Zhang B, Wright AA, Huskamp HA, et al.: Health care costs in the last week of life: Associations with end-of-life conversations. Arch Intern Med 2009;169:480-488.
20. Barnato AE, Chung-Chou HC, Saynina O, et al.: Influence of race on inpatient treatment intensity at the end of life. J Gen Intern Med 2007;22:338-345.